The good news on the economic front has started to roll in once again, with the latest being China-based Oryx Biotech’s announcement to invest $300 million to set up a plasma fractionation plant in Bangladesh.

The company yesterday inked the tripartite agreement with Summit Technopolis, a company of Summit Group, and the Bangladesh Hi-Tech Park Authority (BHTPA) for the country’s first biotech investment at a programme at the ICT Division in Dhaka.

Oryx will set up the plasma fractionation plant on 25 acres of land and building provided by Summit Technopolis to produce plasma derivatives, also known as life-saving therapeutics and other related products.

With a need for plasma in the potential treatment of the COVID-19, this is a timely investment for Bangladesh’s healthcare research and service sectors, Summit Group said in a press release.

Read more